General Biologicals Corporation
TWO: 4117.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Medical - Specialties
- CEO
- Frank Lin
- Headquarters
- Hsinchu City, Taiwan
- IPO year
- 2007
- Market cap
- NT$248.3M
- Website
- https://www.gbc.com.tw
Loading 4117…
Loading profile data…Frequently asked questions about 4117
What does General Biologicals Corporation (4117.TWO) do?
General Biologicals Corporation engages in the research, development, manufacture, and sales of in-vitro diagnostics in Taiwan and internationally. It offers ELISA and chemiluminescence immunoassay, molecular and cell diagnostic, and point of care testing services. The company also provides COVID-19, digital pathology, and contract development m...
Where does 4117.TWO trade?
General Biologicals Corporation (4117.TWO) trades on the Taipei Exchange.
What sector is 4117.TWO in?
General Biologicals Corporation (4117.TWO) operates in the Healthcare sector, specifically in the Medical - Specialties industry.
Who is the CEO of General Biologicals Corporation?
Frank Lin is the chief executive officer of General Biologicals Corporation (4117.TWO).
Where is General Biologicals Corporation headquartered?
General Biologicals Corporation is headquartered in Taiwan.
Does 4117.TWO pay a dividend?
General Biologicals Corporation (4117.TWO) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4117.TWO go public?
General Biologicals Corporation (4117.TWO) completed its initial public offering in 2007.